Procedural Advantages of a Novel Drug-Eluting Coronary Stent
NCT ID: NCT02881216
Last Updated: 2016-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
814 participants
INTERVENTIONAL
2015-01-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Economic Evaluation German Drug-Eluting Stent Registry
NCT00866398
Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
NCT01186133
Adhesiveness of Coronary Drug-Eluting Stents to the Delivery Balloon-Catheter: A Randomized Comparison
NCT00279006
Bioabsorbable Versus Durable Polymer Drug Eluting Stent (DES): a Meta-analysis
NCT01466634
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV: (LONG-DES-IV)
NCT01186094
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Common DES
Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
Currently common drug-eluting stent (DES)
Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
Synergy Stent
Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation
Synergy Stent
Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Synergy Stent
Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
Currently common drug-eluting stent (DES)
Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Bare Metal Stents or Scaffolds
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Heidelberg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Haitham Abu Sharar
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Synergy Stent
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.